<DOC>
	<DOCNO>NCT01707290</DOCNO>
	<brief_summary>The purpose study evaluate safety long-term ivacaftor treatment subject cystic fibrosis ( CF ) Studies 110 ( NCT01614457 ) , 111 ( NCT01614470 ) , 113 ( NCT01685801 ) .</brief_summary>
	<brief_title>Rollover Study Ivacaftor Subjects With Cystic Fibrosis Non G551D CFTR Mutation</brief_title>
	<detailed_description>Ivacaftor first CFTR modulator show improvement CFTR function clinical benefit patient CF . Results Phase 3 study ( VX08-770-102 [ Study 102 ] VX08-770-103 [ Study 103 ] ) show ivacaftor effective treatment patient CF G551D-CFTR mutation , evidence sustained improvement CFTR channel function ( measure reduction sweat chloride concentration ) correspond substantial , durable improvement lung function , pulmonary exacerbation , respiratory symptom , weight gain . Ivacaftor also well tolerate , evidence rate reason premature discontinuation result safety assessment . Ivacaftor ( Trade Name Kalydeco ; 150 mg tablet ) initially approve United States treatment CF patient 6 year age old G551D mutation CFTR gene .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Subjects Study 110 Study 111 enter ivacaftor arm must complete assigned study drug treatment duration previous study Subjects Study 113 enter ivacaftor arm must complete study related treatment Followup Visit meet Study 113 responder criterion previous study . Subjects enter observational arm must complete least 4 week study drug treatment previous study ( Study 110 Study 111 ) , must complete previous study wish enroll ivacaftor arm , must complete previous study meet inclusion criterion ivacaftor arm . Females childbearing potential enter ivacaftor arm must pregnant Subjects enter ivacaftor arm must willing comply contraception requirement Exclusion Criteria ( Ivacaftor Arm Only ) : History illness condition might confound result study pose additional risk administer ivacaftor subject Use moderate strong inhibitor inducer cytochrome P450 ( CYP ) 3A Evidence cataract lens opacity Day 1 Visit</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>